Member news

Relation Therapeutics announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis

Cancer Research Horizons, the innovation arm of Cancer Research UK, is partnering with Diamond Light Source, the UK’s national synchrotron, to build a world-leading fragment-based drug discovery programme.

Stablepharma Named Life Sciences Innovation Awards Winner by Leading US News Platform, Fierce Pharma, in the “Biotech Innovation” Category

OMass Therapeutics Strengthens its Leadership Team with the Promotions of Hsin Loke to Chief Operating officer and Jon Roffey to Senior Vice President, Discovery and Non-Clinical

Today, deepmirror has raised $2.4 million to simplify the adoption of AI for molecule design and enable every company to get drugs to patients faster with their accessible AI-powered platform.

Abselion, an innovator in automated analytical instrumentation that simplifies at-line protein quantification, has secured £6.6 million in Series A financing to bring its award-winning Amperia system to market.

UCL’s Policy Impact Unit, who work closely with researchers in VaxHub Sustainable, VaxHub Global and the FTHM Hub, have recently published a position paper.

Coulter Partners successfully completed a search assignment for Curve Therapeutics (“Curve”) and is pleased to announce the placement of Rab Prinjha, PhD, as Chief Research and Development (R&D) Officer.

The potential presented by Engineering Biology (EngBio), both globally and for the UK, is difficult to overstate. Realisation of this potential across sectors as diverse as health, energy, materials, chemicals production and waste management, will be achieved by providing the right tools to help companies of all sizes as they innovate and translate those innovations to commercial scale.

Brainomix, a pioneer in artificial intelligence (AI) imaging solutions, has been awarded the LSX European Lifestars Award for “Healthtech Company of the Year” by HSBC Innovation Banking, and the “Most Transformative Healthtech Company of the Year” by OBN.

Therakind announces that the United States Patent and Trademark Office has granted a patent protecting the Company’s novel multi-dose, needle-free version of its dry powder nasal drug delivery system, DriDose®.

Stablepharma are delighted to announce that they have been selected to be part of Innovate UK’s prestigious Scaleup Programme, recognising the company's potential to grow exponentially and scale globally.

A new total-body PET scanner that is quicker for the patient and produces higher quality images for faster and earlier diagnosis and treatment of illnesses like cancer and heart conditions, was unveiled by Ministers in London yesterday (Wednesday 27 November).

A new independent report evaluating the economic and scientific impact of the Babraham Research Campus has revealed significant contributions not only to the UK and global life sciences sector, but to the local Cambridge and wider UK economy.

Vitarka Therapeutics Ltd, the EndoPore® cancer therapeutics company, today announced the appointment of Dr John Beadle as the new Chairman of the Board.

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Entia and is pleased to announce the placement of Timothy Broke-Smith as Senior Vice President of Partnerships.

A new industry briefing note developed by Pioneer Group in collaboration with the UK chemicals sector community highlights the urgent need for the sector to transition to a more sustainable, circular economy.

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, recently partnered with Solu Therapeutics (Solu) and is pleased to announce the placement of Sergio Santillana, MD, MSc, MBA, as Chief Medical Officer (CMO).

Dr. Steven Chatfield appointed as Non-Executive Chairman of Bath based company Stablepharma Ltd, following an extensive career in vaccine R&D and Covid19 Pandemic.

Quell Therapeutics CEO, Iain McGill and the team welcomed Rt Hon Rachel Reeves, Chancellor of the Exchequer, to the Translation & Innovation Hub in London to officially open their newly refurbished offices.